Fundz

Immuneering Corp reported raising $37.2 Million in an initial SEC Form D filing, from an offering of $62 Million

PUBLIC · IMRXJan 05, 2021$37.2M of $62M raised

Amount Raised

$37.2 Million

$37.2 Million sold, per SEC Form D (first sale Jan 5, 2021)

Round Type

Venture

CambridgeBiotechnologyHealthcareHealth CareMedicalTherapeutics

Quick answer

Immuneering raised $37.2 Million in a funding round, dated January 5, 2021. Immuneering is based in Cambridge, Massachusetts, United States.

How much did Immuneering raise?
Immuneering raised $37.2 Million in a funding round on January 5, 2021.
What does Immuneering do?
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive.
Where is Immuneering based and how big is it?
Immuneering is based in Cambridge, Massachusetts, United States.
Who are the decision-makers at Immuneering?
Fundz holds 1 contact at Immuneering. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Medical around the same time

Companies in the same sectors as Immuneering that raised within 45 days of this round, from Fundz verified event records.

  • Flyte raised $240K (Seed) on February 18, 2021.
  • Phio Pharmaceuticals raised $14M on February 16, 2021.
  • Design Therapeutics, Inc. raised $125M on February 12, 2021.
  • Acrivon Therapeutics raised $16M on February 12, 2021.
  • ISOThrive raised $5.2M on February 5, 2021.
  • TScan Therapeutics, Inc. raised $100M on January 28, 2021.

Who to call at Immuneering, and when

A new round usually means Immuneering is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Immuneering raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Immuneering, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Immuneering. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Immuneering

Location

245 MAIN STREET, SECOND FLOOR

Cambridge, Massachusetts, United States

About

Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Immuneering raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts5 people are listed at Immuneering. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Immuneering's next move

See what Strategic adds

Immuneering raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.